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Available online 30 June 2016Vγ9Vδ2-T cells constitute the predominant subset of γδ-T cells in human peripheral blood and have been shown
to play an important role in antimicrobial and antitumor immune responses. Several efforts havebeen initiated to
exploit these cells for cancer immunotherapy, e.g. by using phosphoantigens, adoptive cell transfer, and by a
bispeciﬁc monoclonal antibody based approach. Here, we report the generation of a novel set of Vγ9Vδ2-T cell
speciﬁc VHH (or nanobody). VHH have several advantages compared to conventional antibodies related to
their small size, stability, ease of generating multispeciﬁc molecules and low immunogenicity. With high
speciﬁcity and afﬁnity, the anti-Vγ9Vδ2-T cell receptor VHHs are shown to be useful for FACS, MACS and
immunocytochemistry. In addition, some VHH were found to speciﬁcally activate Vγ9Vδ2-T cells. Besides
being of possible immunotherapeutic value, these single domain antibodies will be of great value in the further
study of this important immune effector cell subset.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Cancer1. Introduction
Vγ9Vδ2-T cells constitute the predominant subset of peripheral
blood γδ-T cells with several unique features that can be valuable for
immunotherapeutic approaches. Vγ9Vδ2-T cells become activated by
the MHC-independent recognition of non-peptide phosphoantigens
(pAg) that are produced upon bacterial infection or are upregulated
by malignant cells [1]. Presumably, the type I membrane protein
butyrophilin 3A1 (BTN3A1, also known as CD277) obtains an altered
conformation and membrane distribution upon the detection ofnly Ab; pAg, phosphoantigens;
clear cells; MACS, magnetic-
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BTN3A1 is consequently sensed by the Vγ9Vδ2-T cell receptor (TCR)
resulting in Vγ9Vδ2-T cell activation [2–4]. Stimulation of Vγ9Vδ2-T
cells can be enhanced by interaction between the NKG2D receptor
expressed on most Vγ9Vδ2-T cells and stress-related MICA, MICB and
ULBP molecules, upregulated on infected or transformed cells [5,6].
This allows Vγ9Vδ2-T cells to distinguish normal cells from stressed
cells and to consequently produce large amounts of pro-inﬂammatory
cytokines (e.g. IFN-γ, TNF-α and chemokinesMIP-1 and RANTES) in ad-
dition to cytolytic mediators (perforin, granzyme B) to induce speciﬁc
lysis of cells with elevated pAg levels [7]. In this way, Vγ9Vδ2-T cells
have been shown to be capable of inducing lysis of a broad spectrum
of cancer cells [5,8–10]. Furthermore, upon activation Vγ9Vδ2-T cells
can stimulate the maturation of immature dendritic cells and can also
acquire antigen presenting capacities themselves [11].
Based on these characteristics, several clinical trials were initiated to
evaluatewhether Vγ9Vδ2-T cells could be exploited for immunotherapy
against both hematological and solid malignancies. Trials have included
approaches where aminobisphosphonates (to increase endogenous
pAg levels) or synthetic pAgs were used alone or in combination with
IL-2, and the adoptive transfer of autologous ex vivo expanded Vγ9Vδ2-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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were well tolerated and capable of inducing clinically relevant antitumor
responses in several cases.However, resultswerenot consistent [12,13]. A
possible explanation could be that these therapies were all aimed at sys-
temic (i.e. not tumor-speciﬁc) activation of Vγ9Vδ2-T cells.More recently,
a newVγ9Vδ2-T cell immunotherapy approachwas explored through the
use of a bispeciﬁc antibody. Her2/neu overexpressing pancreatic cells
could efﬁciently be lysed by Vγ9Vδ2-T cells in the presence of a
(Her2)2xVγ9 bispeciﬁc antibody in vitro. When the (Her2)2xVγ9
bispeciﬁc antibodywas co-administeredwith Vγ9Vδ2-T cells on aweekly
basis to immunocompromisedmice inoculated 2 days earlier with a pan-
creatic cancer cell line, signiﬁcantly reduced tumor volumes were ob-
served after 4 weeks [14]. This antibody-based approach adds a new
dimension to the future of Vγ9Vδ2-T cell-based immunotherapy. Howev-
er, the development and use of bispeciﬁc conventional antibody-based
molecules has several limitations, including mispairing of heavy and
light chains and instability [15]. Of interest, and in addition to convention-
al antibodies, camelids (i.e. llamas, camels and dromedaries) also possess
a unique antibody class consisting of heavy chain only antibodies which
lack the light chain and the CH1 domain of the heavy chain [16]. The var-
iable antigen binding region of these antibodies is called a VHH (or
nanobody) and consists of only a single immunoglobulin domain, in con-
trast to full-length antibodies or single-chain variable fragments (scFv)
often used for the design of antibody-based constructs [17]. VHHs can
be used as an attractive alternative to conventional antibodies. Since
VHHs only need to fold one domain they have increased stability, solubil-
ity and ease of refolding. VHHs are ten times smaller than conventional
antibodies which allows them to reach clefts in antigen structures and
provides enhanced tissue penetration as compared to antibodies [18,
19]. VHHs can easily be made into multispeciﬁcity molecules and have a
low immunogenicity. Due to the absence of an Fc-domain, VHHs can be
produced by Escherichia coli or yeast allowing time and cost reduction
[15,20].
Based on the above mentioned unique characteristics of VHHs, we
set out to generate a novel set of Vγ9Vδ2 T cell speciﬁc VHHs and eval-
uate their use for various applications. Our efforts resulted in the identi-
ﬁcation of a panel of Vγ9Vδ2-TCR speciﬁc VHHs, directed against the
Vγ9-chain and/or Vδ2-chain, with activating as well as non-activating
properties. These Vγ9- and Vδ2-TCR directed VHHs could successfully
be used for ﬂowcytometric analysis, isolation of Vγ9Vδ2-T cells bymag-
netic bead isolation, immunocytochemistry and have great potential for
the development of future Vγ9Vδ2-T cell-based immunotherapies.
2. Material & methods
2.1. Cell lines
Jurkat and Jurkat/MAwere cultured in IMDM+medium, i.e. Iscove's
modiﬁed Dulbecco's medium (Lonza, catalog #BE12-722F) supplement-
edwith 10% (v/v) fetal calf serum (FCS) (HyClone GE Healthcare, catalog
#SV30160.03), 0.05 mM β-mercaptoethanol (β-ME), 100 IU/mL sodium
penicillin, 100 μg/mL streptomycin sulfate and 2.0 mM L-glutamine (Life
Technologies, catalog #10378-016). Phoenix-A cells were cultured in
Dulbecco's Modiﬁed Eagle's Medium (Lonza, catalog #BE12-614F)
supplemented with 10% FCS, 0.05 mM β-ME, 100 IU/mL sodium
penicillin, 100 μg/mL streptomycin sulfate and 2.0 mM L-glutamine.
Cell lines were tested mycoplasma negative.
2.2. Flow cytometry and monoclonal antibodies
Antibodies used were FITC-labeled anti-TCR Vδ2 (catalog #555738)
and PE-labeled pan γδ-TCR (catalog #333141) from BD Biosciences
and FITC-labeled anti-TCR Vα24 (catalog #IM1589) and PE-labeled
anti-TCR Vβ11 (catalog #IM2290) from Beckman Coulter. PerCP-
labeled anti-TCR Vδ2 (catalog #331410), PE-labeled anti-TCR Vγ9 (cat-
alog #331308) and APC-labeled anti-TCR Vγ9 (catalog #331310) werefrom Biolegend and FITC-labeled polyclonal swine-anti-rabbit antibody
(catalog #F0205), RPE-labeled goat-anti-mouse F(ab′)2 fragment
(catalog #R0480) and Streptavidin/RPE (catalog #R0480) were obtain-
ed from Dako. APC-labeled goat-anti-mouse F(ab′)2 fragment (catalog
#SC-3818) was obtained from Santa Cruz Biotech and Alexa488-
conjugated goat-anti-rabbit antibody (catalog #A-11008) was from
Thermo Fisher Scientiﬁc. Rabbit-anti-VHH (puriﬁed) clone K1216 and
rabbit-anti-VHH serum clone K976 were obtained from QVQ (on
request). Anti-Myc tag antibody clone 4A6 (catalog #05-724) was
obtained from Merck Millipore and anti-Myc tag antibody clone 9E10
was produced in-house.
All stainings for ﬂow cytometrywere performed in PBS supplement-
ed with 0.1% (w/v) BSA and 0.02% (w/v) sodium-azide. Stained cells
were measured with FACS Calibur or LSRFortessa (BD Biosciences, NJ,
USA) and analyzed and analyzed with CellQuest (BD Biosciences) or
Kaluza software (Beckman-Coulter).
2.3. Generation of donor-derived γδ-T cells
Healthy donor-derived Vγ9Vδ2-T cells were isolated, expanded and
cultured as described [26]. In brief, Vγ9Vδ2-T cells were isolated from
human peripheral blood mononuclear cells (PBMC) by Magnetic-
activated cell sorting (MACS) using FITC-labeled anti-TCR Vδ2 or PE-
labeled anti-TCR Vγ9 antibody in combination with anti-mouse IgG
MicroBeads (Miltenyi Biotec, catalog #130-048-401). Puriﬁed Vγ9Vδ2-T
cells were stimulated weekly with irradiated and aminobisphosphonate
(100 μM Pamidronate for 3 h, Teva Pharmachemie, catalog #12J08RD)
pretreated human mature monocyte derived dendritic cells or an irradi-
ated feeder mixture (PBMC of 2 healthy human donors and Epstein
Barr Virus transformed B cells with addition of 50 ng/mL PHA).
Vγ9Vδ2-T cells were used for experiments when purity was N90%. Of
note, Vγ9Vδ2-T cells used for testing the activation inducing potential
of VHHs had a b 40% CD25 expression.
To obtain Vγ9−Vδ2+, Vγ9+Vδ2−, Vγ9+Vδ2+ and Vγ9−Vδ2− γδ-T
cell lines, we ﬁrst isolated a pan γδ-T cell population. Human PBMC
were stained with a PE-labeled pan γδ-TCR antibody and puriﬁed with
MACS using anti-mouse IgG MicroBeads. This pan γδ-T cell line was
ﬁrst expanded with feeder mixture and then stained with FITC-labeled
anti-TCR Vδ2 and PE-labeled anti-TCR Vγ9 antibodies to allow ﬂow cy-
tometric cell sorting of 4 separate populations (i.e. Vγ9−Vδ2+,
Vγ9+Vδ2−, Vγ9+Vδ2+ and Vγ9−Vδ2− γδ-T cells).
All donor-derived γδ-T cell lines were cultured in Yssels medium
[27] supplemented with 1% AB human serum, 50 U/mL rhIL-2
(Proleukin, Novartis), 0.05 mM β-ME, 100 IU/mL sodium penicillin,
100 μg/mL streptomycin sulfate and 2.0 mM L-glutamine at 37 °C with
5% CO2 in a humidiﬁed atmosphere. Cell lines were tested mycoplasma
negative.
2.4. Generation of Vγ9Vδ2-TCR and Vα24Vβ11-TCR transduced cell lines
Jurkat and Jurkat/MA cell lines expressing TCRs of interest were
generated as described previously [28]. For the Vγ9Vδ2-TCR, protein
sequences of clone G9 Vγ9- and Vδ2-chain [29,30] were used. For the
Vα24Vβ11-TCR, protein sequences of clone NKT12 Vα24- and Vβ11-
chain [31] were used. Sequences of the individual TCR chains were
separated by a picorna virus derived 2 A sequence, codon modiﬁed for
optimal protein production and synthesized by GeneART (Thermo
Fisher Scientiﬁc, MA, USA) after which they were cloned into the LZRS
vector. After transfection to the Phoenix-A packaging cell line, retroviral
supernatants were collected to transduce Jurkat or Jurkat/MA cells in
the presence of retronectin (Takara, catalog #T100A) according to the
manufacturer's protocol [28]. Purity of the transduced cell lines was ob-
tained by MACS cell separation using anti-mouse IgG MicroBeads or by
ﬂow cytometric sorting both in combinationwith FITC-labeled anti-TCR
Vδ2 and PE-labeled anti-TCR Vγ9 antibodies or FITC-labeled anti-TCR
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Vα24Vβ11-TCR cell lines, respectively.
2.5. Immunization of Lama glama
Two Lama glamas were immunized four times each with 1 × 108
human Vγ9Vδ2-T cells of 4–8 different healthy donors in sterile PBS
over a period of six weeks. Blood samples were taken before, at day 28
and at day 43 of the immunization period. To test for serum immune
responses against Vγ9Vδ2-T cells, Vγ9Vδ2-T cells were incubated with
diluted sera. Bound llama antibodies were detected by sequential incu-
bation with rabbit-anti-VHH serum clone K976 and swine-anti-rabbit
FITC antibody and measured by ﬂow cytometry.
2.6. Selection of anti-Vγ9Vδ2-TCR VHH
Phage libraries of immunized llamas were constructed by QVQ
(Utrecht, The Netherlands). In short, extracted RNA isolated from
llama PBMC was transcribed to cDNA and with speciﬁc primers the
VH and subsequently VHH region was ampliﬁed and ligated into the
phagemid vector pUR8100 for display on ﬁlamentous phage [32]. This
resulted in two libraries with approximately 107 transformants each.
Vγ9Vδ2-TCR speciﬁc VHH were enriched by two rounds of phage dis-
play selections. In the ﬁrst round, phages from both libraries were incu-
bated for 2 h at 4 °C with Vγ9Vδ2-TCR transduced Jurkat cells (Jurkat-
Vγ9Vδ2-TCR cells) in HBSS. After incubation, cells were washed and
phages were eluted for 7 min with 100 mM HCl. Eluted phages were
harvested and neutralized with Tris-HCl after which they were used to
infect E. coli. After rescue of the polyclonal pool of selected phages,
non-relevant phages were ﬁrst depleted by two incubations for 1 h at
4 °C with Jurkat cells in HBSS after which unbound phages were used
for selection on Jurkat-Vγ9Vδ2-TCR cells. Phages were eluted and used
to infect E. coli as described for the ﬁrst round selections. Bacteria
were plated on LB-agar plates supplemented with 2% glucose and
100 μg/mL ampicillin (Sigma-Aldrich, catalog #A9518) to generate sin-
gle bacterial colonies containing selected VHH clones. Periplasmic ex-
tracts were made of individual colonies (as described below) and
incubated with a 1:1 mixture of Jurkat-Vγ9Vδ2-TCR and Jurkat cells
(the latter stained with 40 nM CFSE (Sigma-Aldrich, catalog #21888).
VHH speciﬁcally binding to Jurkat-Vγ9Vδ2-TCR cells were detected
with anti-Myc-tag antibody clone 4A6 and an APC-labeled goat-anti-
mouse F(ab′)2 fragment, and selected for production and further
characterization.
2.7. Production and puriﬁcation of VHH
VHHDNA from individual clones was cloned into plasmid pMEK219
(a kind gift ofMohamed El Khattabi (QVQ, Utrecht, The Netherlands)), a
derivative from pHen1 [33] with addition of a HC-V cassette to enable
VHH cloning, a C-terminal Myc- and 6× HIS-tag and deletion of the
gene III sequence. TG1 bacteria were transformed with pMEK219-VHH
for protein production. Bacteria were grown to log-phase in 2xYT
(Serva, catalog #48501.01) plus 100 μg/mL ampicillin and 0.1% glucose.
Protein production was induced by addition of a ﬁnal concentration of
1 mM IPTG (Thermo Fisher Scientiﬁc, catalog #R0391). VHH were ob-
tained from the periplasmic space by harvesting the bacteria through
centrifugation (4500 rpm, 10′, 4 °C), re-suspending them in PBS and
subjecting them to a cycle of freeze-thawing. Bacterial debris were
spun down (4500, 30′, 4 °C) and the supernatant was used as periplas-
mic extract.
VHH were puriﬁed from periplasmic extracts by immobilized metal
ion afﬁnity chromatography (IMAC) on Talon resin (Clontech, catalog #
635504). VHH were eluted with 150 mM imidazole and dialyzed twice
against PBS. Puriﬁed VHHs were checked for purity by coomassie
stained protein gel. For biotinylation of VHH, VHH were treated withNHS-D-Biotin (Sigma-Aldrich, catalog #H1759) according to the
manufacturer's protocol.
2.8. Speciﬁcity analysis of isolated VHH
To determine the speciﬁcity of the anti-Vγ9Vδ2-TCR VHHs, 4 ∗ 105
PBMC, 5 ∗ 104 donor-derived γδ-T cells (e.g. Vγ9−Vδ2+, Vγ9+Vδ2−,
Vγ9+Vδ2+ or Vγ9−Vδ2−) or 5 ∗ 104 (TCR transduced) Jurkat cells
were incubated with 100–500 nM puriﬁed (biotinylated) VHH. Bound
VHH was detected with anti-Myc-tag antibody clone 4 A6 and APC-or
RPE-labeled goat-anti-mouse F(ab′)2 fragment or in case of biotinylated
VHH, with streptavidin/RPE.
2.9. Activation of Vγ9Vδ2-TCR transduced Jurkat/MA cells by Vγ9Vδ2-TCR
speciﬁc VHH
To determine the capacity of the Vγ9Vδ2-TCR VHHs to induce acti-
vation of Vγ9Vδ2-TCR, an assay based on the Jurkat/MA luciferase sys-
tem was used as described previously [34]. A 96-well ﬂat bottom
culture plate was coated overnight with 4 μg/mL anti-Myc-tag clone
9E10 antibody in PBS. In a separate plate, 105 HeLa cells were seeded.
The following day, the anti-Myc coated plate was washed, blocked
with 4% (w/v) BSA in PBS and incubated with 100 nM VHH in PBS
after which excess VHH was washed away. To the plate seeded with
HeLa cells, 0 or 50 μM of the aminobiphosphonate Pamidronate was
added for 3 h at 37⁰C after which wells were carefully washed. To both
plates, 105 Jurkat/MA cells carrying a luciferase gene under NFAT tran-
scriptional control [21] and transduced with a Vγ9Vδ2-TCR (Jurkat/
MA-Vγ9Vδ2-TCR cells), were added in IMDM+medium and incubated
for 24 h at 37⁰C. The next day, 50 ng/mL PMA and 500 ng/mL ionomycin
was added for 4 h at 37⁰C to the positive control conditions. To stop the
assay, all wells were washed with PBS after which Jurkat/MA-Vγ9Vδ2-
TCR cells were lysed with Luciferase Cell Culture Lysis Reagent
(Promega, catalog #E1531). Luminescence was measured by addition
of Luciferase assay reagent (Promega, catalog #E1483) according to
the manufacturer's protocol. Luminescence was measured on a Lumat
LB 9507 luminometer (EG and G Berthold, Bad Wildbad, Germany).
2.10. Magnetic-activated cell sorting with VHH
45–90 ∗ 106 human PBMC were incubated with 0.5 μg biotinylated
VHH to isolate Vγ9Vδ2-T cells from PBMC via positive selection with
anti-BiotinMicroBeads (Miltenyi Biotec, catalog #130-090-485) accord-
ing to the manufacturer's protocol.
2.11. Immunocytochemistry with VHHs
VHH used for immunocytochemistry were produced in a similar
way as described above, with some adjustments. VHH was cloned to
plasmid pMEK220 (kindly provided by Mohamed El Khattabi (QVQ,
Utrecht, The Netherlands)), a variant of pMEK219 with the absence of
a C-terminal Myc- and 6× HIS-tag. Produced VHH was puriﬁed using
a HITrap protein A HP column (catalog #17-0402-01) and desalted
using a HITrap Desalting column (catalog #29-0486-84) on an
ÄKTAxpress (all from GE Healthcare, Zeist, The Netherlands) using the
manufacturer's protocol.
Cytospins were made by spinning Jurkat, Jurkat-Vγ9Vδ2-TCR,
healthy donor-derived Vγ9Vδ2-T cells or Vα24β11-T cells on Starfrost
slides (Knittel) and allowing them to dry overnight. Cells were ﬁxed
with 4% PFA in 0.1MPHEMbuffer pH 6.9 and 100mMammoniumchlo-
ride in PBS was used for quenching. Blocking was performed with
blocking buffer (Elly van Donselaar, personal communication, manu-
script in preparation): 0.5% (w/v) gelatin from cold water ﬁsh skin
(Sigma-Aldrich, catalog #G7765) plus 0.1% (v/v) BSA-c (Aurion, catalog
# 900.099) followed by incubationwith 500nMVHH in the samebuffer.
Bound VHH was detected with rabbit-anti-VHH (clone K1216) and
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were co-stained with DAPI to visualize nuclei.
For cryosections, 50 ∗ 106 Jurkat or Jurkat-Vγ9Vδ2-TCR cells were
pelleted and resuspended in Tissue Tek OCT Compound (Sakura, catalog
#4583). The tube with pelleted cells was snap frozen in liquid nitrogen
and stored at −80 °C. A cryostat (CM 1850 UV, Leica, Wetzlar,
Germany) was used to cut 5 μM sections which were transferred to
Starfrost slides and stained as described above for cytospin slides.
Coverslips were mounted with ProLong Gold (Thermo Fisher
Scientiﬁc, catalog #P36930) and images were made by wide ﬁeld ﬂuo-
rescent microscopy.
2.12. Statistical analyses
Statistical analyseswere performed in GraphPad Prism version 5 (La
Jolla, CA, USA) using paired Student t-tests. Findings were considered
signiﬁcant when p-values were b0.05.
3. Results
3.1. Induction of an anti-Vγ9Vδ2-T cell immune response in Lama glama
In order to generate VHH speciﬁc for the human Vγ9Vδ2-TCR, 2
llamas (named llama A and llama B) were subcutaneously immunized
with 108 puriﬁed human healthy donor-derived Vγ9Vδ2-T cells for
four times over a period of six weeks. The induction of a humoral im-
mune response was followed by testing sera of llama A and B previous
to, midway (day 28) and post immunization (day 42). To this end, puri-
ﬁed Vγ9Vδ2-T cells were incubated with diluted sera and bound llama
antibodies were detected by ﬂow cytometry. Both immunized llamas
display an increasing humoral immune response over the course of
the immunization against Vγ9Vδ2-T cells (Fig. 1).
3.2. Selection of Vγ9Vδ2-TCR speciﬁc VHH
Phage VHH repertoires were synthesized by RT-PCR from peripheral
blood lymphocytes obtained from immunized llama A and B. Vγ9Vδ2-
TCR speciﬁc VHHs were selected by means of phage-display using se-
quential positive and negative selection on a Jurkat cell line genetically
modiﬁed to express the Vγ9Vδ2-TCR (Jurkat-Vγ9Vδ2-TCR) and a non-
transduced Jurkat cell line, respectively (Fig. 2A). After this selection,
190 bacterial periplasmic extracts of single monoclonal VHH clones
were randomly selected and screened for their ability to speciﬁcally
bind the Vγ9Vδ2-TCR. For this purpose, the periplasmic extracts were
incubated with a 1:1 mixture of CFSE-labeled Jurkat cells and non-
labeled Jurkat-Vγ9Vδ2-TCR cells and speciﬁc binding was determinedFig. 1. Immunization of Lama glamawith human healthy donor-derived Vγ9Vδ2-T cells induces
0: open circles) or immune sera (day 28: triangles and day 43: squares) of immunized llamas A
intensity (MF).by ﬂow cytometry. This screening resulted in the identiﬁcation of 42 in-
dividual VHH clones that bound to Jurkat-Vγ9Vδ2-TCR cells but not to
the control Jurkat cell line (Fig. 2B), suggesting speciﬁcity to either the
Vγ9Vδ2-TCR or to CD3 co-expressed in the TCR-complex. After elimina-
tion of poor protein producing clones and sequencing of the remaining
selected clones to exclude duplicates, a set of 20 individual VHH clones
remained; 9 derived from llamaA and11 derived from llamaB. These 20
clones were subsequently tested for binding to CD3 or αβ-TCR using
Jurkat cells genetically modiﬁed to express the invariant Vα24Vβ11
TCR of CD1d-restricted iNKT cells (Jurkat-Vα24Vβ11-TCR cells). Impor-
tantly, whereas all 20 clones were conﬁrmed to bind to Jurkat-Vγ9Vδ2-
TCR cells, none of the clones showed binding to αβ-TCR expressing
Jurkat cells indicating that the selected VHHs were indeed speciﬁc for
the Vγ9Vδ2-TCR and did not cross-react with the αβ-TCR or CD3
(Fig. 2C). However, these data do not exclude binding of the selected
VHHs to conserved constant γδ-TCR domains. The 20 VHH clones
were puriﬁed for further characterization studies.
3.3. Characterization of Vγ9Vδ2-TCR speciﬁc VHHs
To determine whether the anti-Vγ9Vδ2-TCR VHHs were speciﬁc for
the TCR Vδ2- and/or Vγ9- chain, pan γδ-T cells were ﬁrst puriﬁed from
healthy donor-derived PBMC by Magnetic-activated cell sorting
(MACS). After an initial round of expansion, the resulting population
of pan γδ-T cells (98% purity) was separated by ﬂow cytometric sorting
into 4 distinct populations: Vγ9−Vδ2+, Vγ9+Vδ2−, Vγ9+Vδ2+ and
Vγ9−Vδ2− γδ-T cells (Fig. 3A). Binding of the 20 previously selected
and puriﬁed putative Vγ9Vδ2-TCR speciﬁc VHHs to these 4 γδ-T cell
populations was then determined and deﬁned as non-binding, weak,
moderate or strong binding to each population according the mean
ﬂuorescence index (Fig. 3B). As is depicted in Table 1, all selected
VHHs demonstrated binding to Vγ9+Vδ2+ γδ-T cells but not to
Vγ9−Vδ2− γδ-T cells (i.e. γδ-T cells expressing other γ- or δ-TCR
chains). This indicated that none of the VHHs bound to the constant
γδ-TCR region but that they all bound to the variable region of the
TCR. The majority of the tested VHHs were speciﬁc for the Vδ2-TCR
chain, with 5 VHHs showing preferential or exclusive binding to the
Vγ9-TCR chain. Clones 5C1, 6H3, and 6C4 showed reactivity to both
the Vγ9- and the Vδ2-chain, although in all cases therewas a preference
for binding to one of the chains.
In order to gain more knowledge about the characteristics of the
speciﬁc VHHs, we determined the afﬁnity of these VHHs for the
Vγ9Vδ2-TCR. Jurkat-Vγ9Vδ2-TCR cells were incubated with different
concentrations of each VHH and the concentration at which half of the
maximum ﬂuorescence intensitywas reached by ﬂow cytometry analy-
sis, was determined. Most VHHs had an afﬁnity of 1–50 nM with thea strong immune response. Vγ9Vδ2-T cells were incubatedwith diluted pre-immune (day
and B. VHH binding was assessed by ﬂow cytometry. Abbreviations: mean ﬂuorescence
Fig. 2. Screening of bacterial periplasmic extracts of Vγ9Vδ2-TCR speciﬁc VHH clones. A) Dot-plots illustrating Vγ9Vδ2-TCR expression of non-transduced (left) and Vγ9Vδ2-TCR
transduced (right) Jurkat cell lines for the selection of anti-Vγ9Vδ2-TCR VHH. B) After positive and negative selection, VHH clones were screened for binding to Jurkat-Vγ9Vδ2-TCR
and CFSE-labeled Jurkat cells using ﬂow cytometry. Representative dot-plots of binding of the selected VHHs to Vγ9Vδ2-TCR transduced Jurkat cells versus non-transduced Jurkat cells.
The three depicted dot-plots show examples of a Vγ9Vδ2-TCR speciﬁc VHH (left dot-plot; binding to Vγ9Vδ2-TCR transduced Jurkat, but not to Jurkat), a non-Vγ9Vδ2-TCR speciﬁc binding
VHH (middle dot-plot; binding to both Vγ9Vδ2-TCR transduced Jurkat aswell as to Jurkat, i.e. not speciﬁc for theVγ9Vδ2-TCR), and a non-speciﬁc VHH (right dot-plot; no binding to either
Vγ9Vδ2-TCR transduced Jurkat or Jurkat).
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350 nM (data not shown).
Since Vγ9Vδ2-T cells are promisingwith respect to cancer immuno-
therapy [1], we explored whether the Vγ9Vδ2-TCR speciﬁc VHHs wereFig. 3. Assessment of the chain speciﬁcity and binding strength of anti-Vγ9Vδ2-TCR VHHs. A) A
cell populations by ﬂow cytometric sorting. Indicated is the purity of the cell lines after sorti
Vγ9+Vδ2−, Vγ9+Vδ2+ and Vγ9−Vδ2− γδ-T cell populations was deﬁned. The mean ﬂuore
determining the ratio between the mean ﬂuorescence intensity of a VHH with that of a negat
weak binding (±, MFI 1.5–4.5), moderate binding (+, MFI 4.6–20) or strong binding (++, MFcapable of activating Vγ9Vδ2-T cells. For this purpose, Jurkat/MA cells
carrying a luciferase gene under the control of an NFAT-regulated pro-
moter [21], were retrovirally transduced to express the Vγ9Vδ2-TCR.
The established Jurkat/MA-Vγ9Vδ2-TCR cell line produces levels ofpan γδ-T cell line was split into Vγ9−Vδ2+, Vγ9+Vδ2−, Vγ9+Vδ2+ and Vγ9−Vδ2− γδ-T
ng. B) Representative histograms illustrating how VHH binding intensity to Vγ9−Vδ2+,
scence index (MFI) of each VHH to an individual γδ-T cell population was calculated by
ive control VHH. VHH binding intensity was then deﬁned as non-binding (−, MFI b 1.5),
I N 20).
Table 1
Vγ9Vδ2-TCR speciﬁc VHH with indicated TCR chain speciﬁcitya.
VHH Binds γδ-T cell population
Vγ9−Vδ2+ Vγ9+Vδ2− Vγ9+Vδ2+ Vγ9−Vδ2−
5C1 ± ++ ++ −
5D3 ++ − ++ −
5E3 − ++ ++ −
5G3 − ++ ++ −
5F5 ++ − ++ −
5C7 ± − ± −
5D7 ++ − ++ −
5E7 ++ − ++ −
5C8 ++ − ++ −
5B11 − − + −
6A1 ++ − ++ −
6C1 ++ − ++ −
6H1 − ++ ++ −
6E3 ++ − ++ −
6G3 ++ − ++ −
6H3 ++ ± ++ −
6C4 ± ++ ++ −
6E4 ++ − ++ −
6H4 ++ − ++ −
6F6 ++ − ++ −
a Distinct γδ-T cell populations were obtained by ﬂow cytometric sorting of a donor-
derived pan γδ-T cell line. The mean ﬂuorescence index (MFI) of each VHH to an individ-
ual γδ-T cell population was calculated by determining the ratio between the mean ﬂuo-
rescence intensity of a VHHwith that of a negative control VHH studied byﬂow cytometry
(n = 3). VHH binding intensity was then deﬁned as non-binding (−, MFI b 1.5), weak
binding (±, MFI 1.5–4.5), moderate binding (+, MFI 4.6–20) or strong binding (++,
MFI N 20).
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activate Vγ9Vδ2-T cells (positive controls: PMA/ionomycin or
aminobisphosphonate pretreated HeLa cells that express enhanced
levels of pAg) showed enhanced luciferase activity, while stimuli ex-
pected not to activate Vγ9Vδ2-T cells (negative controls: medium,
HeLa cells or control VHH) showed baseline levels of luciferase activity
indicating the established Jurkat/MA-Vγ9Vδ2-TCR luciferase system to
be a reliable method to test Vγ9Vδ2-T cell activation (Fig. 4). In order
to test the activating potential of individual Vγ9Vδ2-TCR speciﬁc
VHHs, VHHs were captured to culture plates and cultured for 24 h
with Jurkat/MA-Vγ9Vδ2-TCR cells after which luciferase activity inFig. 4. Differential activation of individual Vγ9Vδ2-TCR speciﬁc VHHs in an NFAT
regulated luciferase reporter system. Jurkat/MA were retrovirally transduced to express
Vγ9Vδ2-TCR. Jurkat/MA-Vγ9Vδ2-TCR cells were incubated for 24 h with indicated
positive and negative control conditions or plate-bound Vγ9Vδ2-TCR speciﬁc VHHs. As a
positive control, Jurkat/MA-Vγ9Vδ2-TCR cells were stimulated with 50 ng/mL PMA and
500 ng/mL ionomycin for 4 h. Luciferase activity was calculated relative to measured
luminescence induced by control VHH and expressed as relative luminescence units
(RLU) and set to one. Abbreviations: PMA/iono (PMA and ionomycin); HeLa (HeLa
untreated cells); HeLa + NBP (aminobisphosphonate pretreated HeLa cells); control
VHH (non-Vγ9Vδ2-TCR speciﬁc VHH).Jurkat/MA-Vγ9Vδ2-TCR cell lysates was measured. The capacity to in-
duce activation of Jurkat/MA-Vγ9Vδ2-TCR cells varied considerably
among the different Vγ9Vδ2-TCR speciﬁc VHHs (Fig. 4). Some clones
were not able to trigger Jurkat/MA-Vγ9Vδ2-TCR cell activation, while
others were substantially more potent than established positive con-
trols. We conﬁrmed that the activating Vγ9Vδ2-TCR speciﬁc VHHs
were also capable of inducing activation, degranulation and cytokine
production of Vγ9Vδ2-T cell lines obtained from healthy volunteers
(data not shown) indicating the potential of these VHHs to be further
developed for e.g. cancer immunotherapeutic approaches (R.C.G. de
Bruin et al., manuscript in preparation).
3.4. Vγ9Vδ2-TCR speciﬁc VHH are able to identify speciﬁc T-cell subsets in
cytometry
Sincewe found such a broad panel of Vδ2- and/ or Vγ9-chain speciﬁc
VHHswith bothVγ9Vδ2-T cell activating and non-activating properties,
we evaluated their use for several research and diagnostic applications
as these novel reagents could be of great value for the scientiﬁc and
health care community interested in Vγ9Vδ2-T cell biology.
First, we tested whether the Vγ9Vδ2-TCR speciﬁc VHHs could be
used for ﬂow cytometry. For this purpose, we selected two VHHs from
our panel with the highest afﬁnity for the Vδ2-chain (VHH 6H4,
3.3 nM) and for theVγ9-chain (VHH6H1, 2.8 nM). These VHHswere bi-
otinylated for straightforward detection using ﬂuorescently labeled
streptavidin. A donor-derived Vγ9Vδ2-T cell line was stained with two
commercially available Vδ2- andVγ9-TCR speciﬁc antibodies to conﬁrm
its purity (Fig. 5A). In separate stainings, either the Vδ2-TCR speciﬁc or
the Vγ9-TCR speciﬁc commercially available antibody was replaced by
the biotinylated Vδ2-speciﬁc VHH6H4 or the Vγ9-speciﬁc VHH6H1, re-
spectively. Staining of a healthy donor-derived Vγ9Vδ2-T cell line with
either the Vδ2-TCR speciﬁc VHH or the Vγ9-TCR-speciﬁc VHH resulted
in a similar staining pattern and similar Vγ9Vδ2-T cell frequencies as
obtained with the commercially available antibodies (Fig. 5A). To
further substantiate the usefulness of these VHHs for ﬂow cytometry,
human peripheral blood mononuclear cells (PBMC) were also stained
with Vδ2- and Vγ9-TCR speciﬁc VHHs. The staining of PBMC with
either commercially available anti-Vδ2 and anti-Vγ9 antibodies or the
Vδ2- and Vγ9-TCR speciﬁc VHHs showed exactly the same frequency
of the Vγ9Vδ2-T cell population (1.18%) (Fig. 5B). Based on differences
in mean ﬂuorescence intensity, the discriminatory potential of VHH
6H4 appeared to be superior compared to that of the commercially
available anti-Vδ2 monoclonal antibody (Fig. 5B). Taken together,
these data indicate that Vδ2-TCR speciﬁc VHH6H4 andVγ9-TCR speciﬁc
VHH 6H1 are suitable tools for use in ﬂow cytometry .
3.5. Vγ9Vδ2-TCR speciﬁc VHH are powerful tools for Vγ9Vδ2-T cell isolation
Since VHH 6H4 and VHH 6H1 bind Vγ9Vδ2-T cells with high
speciﬁcity, we reasoned that these VHHs might also be excellent tools
for cell puriﬁcation purposes. A common method used in the ﬁeld to
separate and purify various cell populations is Magnetic-activated cell
sorting (MACS). With this method, magnetic beads are coupled with
an antibody that binds to an antigen presented on the cell membrane
of the cell population of interest. To assess if our VHHs could be used
for this method, biotinylated Vδ2-speciﬁc VHH 6H4 and biotinylated
Vγ9-speciﬁc VHH 6H1 were used in combination with anti-biotin
MicroBeads to generate an enriched Vγ9Vδ2-T cell population from
PBMC (a representative example of Vδ2-enrichment is shown in
Fig. 6A). Percentages of Vγ9Vδ2-T cells are generally low in human
PBMC (0.5–5%), but could be strikingly enriched by VHH-based MACS
puriﬁcation. Using VHH 6H4, cell populations were signiﬁcantly
enriched from 1.6 ± 1.1% Vδ2+ cells in the PBMC fraction to 91 ± 10%
Vδ2+ cells (n= 15, p b 0.0001) in the fraction after MACS with a yield
of 49 ± 21%, similar to puriﬁcation with a commercially available anti-
Vδ2monoclonal antibody (data not shown). For Vγ9+ cells enrichment,
Fig. 5. Vδ2-speciﬁc and Vγ9-speciﬁc VHHs are suitable tools for use in ﬂow cytometry. Frequency of Vγ9+Vδ2+ T cells within a population was determined using a ﬁxed number of a
donor-derived Vγ9Vδ2-T cell line (A) or PBMC from the same donor (B). Frequency of Vγ9Vδ2-T cells within the population as determined using commercially available PE-
conjugated anti-Vγ9 (5 μg/mL) or FITC-conjugated anti-Vδ2 (5 μg/mL) antibodies for ﬂowcytometry (left). The anti-Vγ9 (top) or anti-Vδ2 (bottom) antibodies are replaced bybiotinylated
Vγ9-speciﬁc VHH 6H1 (1.5 μg/mL) or biotinylated Vδ2-speciﬁc VHH 6H4 (1.5 μg/mL), respectively and detected with streptavidin-APC.
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the PBMC fraction to as high as 95 ± 5% Vγ9+ cells (n = 15,
p b 0.0001) in the fraction after MACS with a yield of 70 ± 22% when
using the VHH 6H1 (see Fig. 6B and Table 2). For 3 random PBMC do-
nors, the cells were cultured after puriﬁcation for at least 3 weeks by a
weekly stimulation with feeder mixture plus PHA and IL-2. In one
week, VHH MACS isolated Vγ9Vδ2-T cells expanded with an average
of 5.4 ± 2.3 fold for cell populations enriched by Vδ2-speciﬁc VHH
6H4 and with an average of 5.5 ± 2.1 fold for cell populations enriched
by Vγ9-speciﬁc VHH 6H1 (mean ± SD, n= 3, data not shown). These
results show that both the Vδ2-speciﬁc VHH 6H4 and the Vγ9-speciﬁc
VHH 6H1 can be used to isolate Vδ2+ and Vγ9+-T cells from PBMCwith high purity and yield and that these isolated cells can be
maintained and expanded in cell culture.
3.6. Vγ9Vδ2-TCR speciﬁc VHH are reactive in immunocytochemistry
Currently, there is a limited number of Vδ2- and Vγ9-TCR speciﬁc
antibodies available for the detection of Vγ9Vδ2-T cells in immunocyto-
chemistry. To this end, we examined if the Vδ2- and Vγ9 speciﬁc VHHs
could be used to detect Vγ9Vδ2-T cells on cytospins and cryosections.
For cytospin slides, Jurkat and Jurkat-Vγ9Vδ2-TCR (Fig. 7A) as well as
healthy donor-derived Vγ9Vδ2-T and Vα24Vβ11-T cells (Fig. 7B)
were spun on glass slides and stained with either Vδ2-speciﬁc VHH
Fig. 6. Vδ2-speciﬁc and Vγ9-speciﬁc VHHs can be used for Vγ9Vδ2-T cell puriﬁcation. Human PBMC were incubated with either biotinylated Vδ2-speciﬁc VHH 6H4 or biotinylated Vγ9-
speciﬁc VHH 6H1 to allow cell separation byMACS using anti-biotin MicroBeads. A) Representative ﬁgure of Vδ2+ isolated cells from PBMC using VHH 6H4. Percentages of Vγ9+Vδ2+-T
cells in the population are shown before MACS (left) and of the two cell populations after MACS; positive fraction (post MACS, middle dot-plot) and negative fraction (right dot-plot).
B) Percentage of Vδ2+ or Vγ9+-T cells in the cell population before (pre MACS) and after MACS (post MACS) using VHH 6H4 or VHH 6H1, respectively. Shown are mean ± SD of n=
15. p b 0.0001.
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Jurkat-Vγ9Vδ2-TCR cells (TCR expression 92%) as well as the healthy
donor-derived Vγ9Vδ2-T cells (TCR expression 97%) that were stained
with either the Vγ9-or the Vδ2-TCR speciﬁc VHH, nearly 100% of the
cells stained positively. As expectedwith staining a cell surface receptor,
the staining pattern of the TCR was restricted to the cell membrane
(Fig. 7A and B). The observed staining was speciﬁc for the Vγ9Vδ2-
TCR as neither non-transduced Jurkat cells (not expressing a TCR), nor
T-cells expressing anαβ-TCR (TCR expression 96%), nor slides not incu-
bated with VHH (negative control) showed staining with the VHHs.
Next, we explored if the VHHs could also be used for immunocyto-
chemistry staining of Vγ9Vδ2-T cells in cryosections. To this end, 5 μM
sections were made of snap frozen Jurkat or Jurkat-Vγ9Vδ2-TCR cells
and incubated with Vδ2-speciﬁc VHH 6H4, Vγ9-speciﬁc VHH 6H1 or
no VHH as negative control. Staining of Vγ9Vδ2-T cells in cryosections
showed a similar result as for the staining of Vγ9Vδ2-T cells in
cytospins; VHH 6H4 and VHH 6H1 showed speciﬁc staining of nearly
all Jurkat-Vγ9Vδ2-TCR cells (TCR expression 89%) but did not show
staining of Jurkat cells without TCR expression or cryosections not incu-
bated with VHH (Fig. 7C). These observations indicate that Vδ2-speciﬁc
VHH 6H4 and Vγ9-speciﬁc VHH 6H1 can be used to detect Vγ9Vδ2-T
cells in cytospins of cell suspensions and cryosections containing
human Vγ9Vδ2-T cells.Table 2
MACS cell seperation using anti-Vγ9Vδ2-TCR VHHsa.
Pre MACS (purity %)
VHH 6H4 (Vδ2-speciﬁc) 1.6 ± 1.1 (0.5–4.6)
VHH 6H1 (Vγ9-speciﬁc) 1.6 ± 0.8 (0.6–3.1)
a Vδ2+ or Vγ9+-T cells were isolated from human PBMC using either biotinylated Vδ2-speciﬁ
Vδ2+ or Vγ9+-T cells within the population are shown before (preMACS) and afterMACS (pos
MACS to 100%. n= 15, shown are mean ± SD and the range in parentheses.4. Discussion
Vγ9Vδ2-T cells have the ability to distinguish “normal” cells from
“altered” cells by the MHC-independent recognition of elevated pAg
levels due to bacterial infection or malignancy. When activated,
Vγ9Vδ2-T cells can produce large amounts of cytokines, chemokines
and cytotoxic mediators to efﬁciently kill their targets [7]. In addition,
activated Vγ9Vδ2-T cells can act as antigen presenting cells for αβ-T
cells, inducing a predominantly pro-inﬂammatory cytokine proﬁle and
they are able to stimulate the maturation of immature dendritic cells
[11,22]. These functions make Vγ9Vδ2-T cells attractive for use in
immunotherapy.
Here, we set out to generate VHH antibody fragments against the
Vγ9Vδ2-TCR. VHH are smaller than conventional antibodies or scFvs
and consist of a single domain. Moreover, VHH do not require the pres-
ence of a light chain and are characterized by high stability, good solu-
bility, strong ability to easily refold and low immunogenicity. Also,
multispeciﬁc molecules can be easily generated by DNA cloning and
production can be performed in E. coli or yeast reducing production
costs [15,18,20]. Their small size allows enhanced tissue penetration
but also rapid clearing by the kidneys in vivo. However, the latter can
be circumvented by fusion to an anti-albumin VHH which prolongs
the in vivo half-life [19,23].Post MACS (purity %) Yield (%)
91 ± 10 (65–100) 49 ± 21 (12–88)
95 ± 5 (83–100) 70 ± 22 (11–94)
c VHH 6H4 or biotinylated Vγ9-speciﬁc VHH 6H1 and anti-biotinMicroBeads. Presence of
t MACS). Yield is calculated by setting the amount of Vδ2+ or Vγ9+-T cells in PBMC before
Fig. 7. Immunocytochemistry staining of Vγ9Vδ2-TCR using VHHs. Jurkat and Jurkat-Vγ9Vδ2-TCR cells (A, C) or healthy donor-derived Vγ9Vδ2-T and Vα24Vβ11-T cells (B) were
incubatedwith Vδ2-speciﬁc VHH6H4, Vγ9-speciﬁc VHH6H1ornoVHH. BoundVHHwasdetectedwith a rabbit-anti-VHHantibody and anAlexa488-conjugated goat-anti-rabbit antibody
and imaged by wide ﬁeld ﬂuorescent microscopy. A–B) Cytospin slides stained with VHH. C) Cryosections stained with VHH.
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phage-display and screenings, we obtained a panel of 20 diverse VHHs
that did not cross-react with CD3 (co-expressed in the TCR-complex)
or other TCRs. We have found that all VHHs bind to the variable region
of the γδ-TCR and have speciﬁcity for either the Vγ9- or the Vδ2-chain.
Surprisingly, we also found some VHHs which recognize both chains,
but with a preference for one chain over the other chain. Presumably
the latter group of VHHs recognizes an epitope that is composed of a re-
gion of both chains where these are in close proximity.
From the broad panel of anti-Vγ9Vδ2-TCR VHHs, we decided to fur-
ther explore possible applications of our strongest Vδ2 binding VHH
(VHH 6H4) and strongest Vγ9-chain binding VHH (VHH 6H1). Both
these VHHs were able to speciﬁcally detect γδ-T cell populations
expressing only the chain towhich theVHHwasdirected inﬂow cytom-
etry; Vδ2+ populations for VHH 6H4 and Vγ9+ populations for VHH
6H1. These VHHs were successfully applied both in staining Vγ9Vδ2-T
cells of cultures with a dominant presence of Vγ9Vδ2-T cells as well as
for the identiﬁcation of Vγ9Vδ2-T cells within a large pool of other
cells, such as PBMC where Vγ9Vδ2-T cells are only present in percent-
ages as low as 1–5%. This indicates that these VHHs have high speciﬁcity
with negligible non-speciﬁc binding to other cells. Furthermore, the
mean ﬂuorescence intensity obtained by Vδ2-TCR speciﬁc VHH 6H4
stained in ﬂow cytometry, appears to be higher compared to the stain-
ing with a commercial anti-Vδ2 monoclonal antibody. The highly dis-
criminating capacity of these VHHs would also make them very good
tools for ﬂow cytometric sorting.
The highly speciﬁc staining of Vγ9Vδ2-T cells with VHH 6H4 and
VHH 6H1 allows these VHH also to be used for Vγ9Vδ2-T cell enrich-
ment from PBMC by MACS. Both VHH 6H4 as well as VHH 6H1 provide
high enrichment and yield of Vδ2+ or Vγ9+ populations, respectively,when used for their isolation from PBMC. Furthermore, isolated popula-
tions can be successfully cultured for at least 3 weeks by a weekly stim-
ulation of feeder mixture plus PHA and IL-2. This could provide an
excellent method for the culturing of Vγ9Vδ2-T cell populations for
research purposes or even adoptive transfer therapies.
Both the Vδ2-speciﬁc VHH 6H4 and the Vγ9-speciﬁc VHH 6H1
could speciﬁcally stain Jurkat-Vγ9Vδ2-TCR cells as well as healthy
donor-derived Vγ9Vδ2-T cells on cytospin slides. Also, we found
that the Vδ2-speciﬁc VHH 6H4 and the Vγ9-speciﬁc VHH 6H1 could
be used to detect Vγ9Vδ2-TCR expressing cells in cryosections with
similar success. The stainings were strictly Vγ9Vδ2-TCR speciﬁc as
Jurkat cells that did not express a TCR, or Jurkat cells not incubated
with VHH, did not show a signal. Though some Vδ2- and Vγ9-
speciﬁc antibodies are currently on the market for the use in immu-
nocytochemistry, not all antibodies perform well in this application
and the choice is limited. Our data indicate that VHH 6H4 and VHH
6H1 could expand the set of antibody (− fragments) available for
the detection of Vδ2+ and Vγ9+-T cells in immunocytochemistry.
The detection of Vγ9Vδ2-T cells with immunocytochemistry pro-
vides opportunities for both research and diagnostics applications
that focus on detecting Vδ2+ or Vγ9+-T cells in e.g. healthy or dis-
eased tissue, tumors as well as PBMC.
Among the panel of Vγ9Vδ2-TCR VHHs, we found both activating
and non-activating Vγ9Vδ2-T cell VHHs. ActivatingVHHs could be of in-
terest for the development of cancer immunotherapeutics in which an
enhanced Vγ9Vδ2-T cell function is desired. Recently, a bispeciﬁc
(Her2)2xVγ9 antibody construct has been developed to direct
Vγ9Vδ2-T cells more speciﬁcally to Her2 overexpressing tumor cells in
order to enhance tumor cell lysis. This approach was exploited for pan-
creatic cancer cells both in vitro and in vivowith success [14]. However,
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light chain domains which come with several limitations, the use of
VHHs would be a preferential alternative [15,24].
With respect to the non-activating Vγ9Vδ2-T cell VHHs, it would
be interesting to investigate if these VHHs could also provide neu-
tralization of the Vγ9Vδ2-TCR in the presence of elevated pAg levels.
Patients treated with aminobisphophonates for osteoporosis or pre-
vention of fractures due to bone metastasis, present with elevated
levels of pAg as a side-effect of this treatment [11]. The elevated
pAg levels induce a systemic activation of Vγ9Vδ2-T cells that can
lead to bothersome acute phase reaction symptoms like fever, mus-
cle ache and shivering. To date, multiple clinical studies have
attempted to reduce the systemic activation of Vγ9Vδ2-T cells in
this setting but so far without success [25]. When identiﬁed in our
panel of VHHs, a neutralizing anti-Vγ9Vδ2-TCR VHH could constitute
a novel and promising approach to dampen these side-effects of
aminobisphosphonate treatment.
Taken together, the data reported here show that the obtained anti-
Vγ9Vδ2-TCR VHHs bind Vγ9Vδ2-T cells with high speciﬁcity making
them valuable tools for the detection and enrichment of Vγ9Vδ2-T
cells using ﬂow cytometry, MACS and immunocytochemistry, which is
relevant both for research and diagnostic purposes. Furthermore,
these VHHs can be promising for the development of future immuno-
therapeutics either aimed at the activation or possibly neutralization
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